Show simple item record

dc.contributor.authorWhelan, Megan F.
dc.contributor.authorO'Toole, Therese E.
dc.contributor.authorChan, Daniel L.
dc.contributor.authorRozanski, Elizabeth A.
dc.contributor.authordeLaforcade, Armelle M.
dc.contributor.authorCrawford, Sybil L.
dc.contributor.authorCotter, Susan M.
dc.date2022-08-11T08:11:05.000
dc.date.accessioned2022-08-23T17:32:22Z
dc.date.available2022-08-23T17:32:22Z
dc.date.issued2009-04-01
dc.date.submitted2010-03-01
dc.identifier.citationJ Vet Emerg Crit Care (San Antonio). 2009 Apr;19(2):158-64. <a href="http://dx.doi.org/10.1111/j.1476-4431.2009.00403.x">Link to article on publisher's site</a>
dc.identifier.issn1476-4431 (Linking)
dc.identifier.doi10.1111/j.1476-4431.2009.00403.x
dc.identifier.pmid19691566
dc.identifier.urihttp://hdl.handle.net/20.500.14038/50935
dc.description.abstractOBJECTIVE: To determine the utility of human intravenous immunoglobulin (hIVIG) for the initial treatment of canine immune-mediated hemolytic anemia (IMHA). DESIGN: Blinded, randomized, clinical trial. SETTING: Veterinary teaching hospital. ANIMALS: Twenty-eight, client-owned dogs with primary IMHA. INTERVENTIONS: At enrollment, after diagnosis of IMHA, dogs were randomly assigned to receive either hIVIG or placebo, in a blinded fashion. For the next 14 days, all dogs received glucocorticoids as the sole immunosuppressant agent. All dogs received low-molecular-weight heparin as an anticoagulant. D-dimer concentrations were evaluated at the beginning and end of the study protocol to monitor for thromboembolic complications. MEASUREMENTS AND MAIN RESULTS: Twenty-five of 28 dogs (89%) were discharged from the hospital. Thirteen of those received hIVIG and 12 received placebo. Twenty-four dogs (86%) were alive 14 days after enrollment, and of these 13 received hIVIG and 11 received placebo. D-dimer concentrations were elevated in 86% of all dogs at the time of diagnosis. CONCLUSIONS: For initial treatment of dogs with IMHA, the addition of hIVIG to corticosteroid treatment did not improve initial response, nor did it shorten hospitalization.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=19691566&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1111/j.1476-4431.2009.00403.x
dc.subjectAnemia, Hemolytic, Autoimmune
dc.subjectAnimals
dc.subjectDog Diseases
dc.subjectDogs
dc.subjectFemale
dc.subjectGlucocorticoids
dc.subjectHumans
dc.subjectImmunoglobulins, Intravenous
dc.subjectMale
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.subjectWomen's Studies
dc.titleUse of human immunoglobulin in addition to glucocorticoids for the initial treatment of dogs with immune-mediated hemolytic anemia
dc.typeJournal Article
dc.source.journaltitleJournal of veterinary emergency and critical care (San Antonio, Tex. : 2001)
dc.source.volume19
dc.source.issue2
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/wfc_pp/462
dc.identifier.contextkey1182197
html.description.abstract<p>OBJECTIVE: To determine the utility of human intravenous immunoglobulin (hIVIG) for the initial treatment of canine immune-mediated hemolytic anemia (IMHA).</p> <p>DESIGN: Blinded, randomized, clinical trial.</p> <p>SETTING: Veterinary teaching hospital.</p> <p>ANIMALS: Twenty-eight, client-owned dogs with primary IMHA.</p> <p>INTERVENTIONS: At enrollment, after diagnosis of IMHA, dogs were randomly assigned to receive either hIVIG or placebo, in a blinded fashion. For the next 14 days, all dogs received glucocorticoids as the sole immunosuppressant agent. All dogs received low-molecular-weight heparin as an anticoagulant. D-dimer concentrations were evaluated at the beginning and end of the study protocol to monitor for thromboembolic complications.</p> <p>MEASUREMENTS AND MAIN RESULTS: Twenty-five of 28 dogs (89%) were discharged from the hospital. Thirteen of those received hIVIG and 12 received placebo. Twenty-four dogs (86%) were alive 14 days after enrollment, and of these 13 received hIVIG and 11 received placebo. D-dimer concentrations were elevated in 86% of all dogs at the time of diagnosis.</p> <p>CONCLUSIONS: For initial treatment of dogs with IMHA, the addition of hIVIG to corticosteroid treatment did not improve initial response, nor did it shorten hospitalization.</p>
dc.identifier.submissionpathwfc_pp/462
dc.contributor.departmentDepartment of Medicine, Division of Preventive and Behavioral Medicine
dc.source.pages158-64


This item appears in the following Collection(s)

Show simple item record